Biotechs beat Big Pharma as patients lose faith with giants

Anyone who tells you that there's no such thing as bad publicity never worked in the pharma business. A new survey shows that GlaxoSmithKline ($GSK) and some of its pharma rivals have seen their negative ratings soar in the wake of damaging admissions as patients lose faith with some of the biggest drug peddlers. Running against the trend: Gilead ($GILD) and Lundbeck, which got top marks for transparency and integrity. Novartis ($NVS) came in third. Story

Suggested Articles

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.

Boehringer signed a deal to buy out a small immuno-oncology player this morning, and AbbVie’s been at it, too, inking a deal to snap up Mavupharma.